First Identified Cases of SARS-CoV-2 Variant B.1.1.7 in Minnesota — December 2020–January 2021
Weekly / February 26, 2021 / 70(8);278–279
On February 17, 2021, this report was posted online as an MMWR Early Release.
Melanie J. Firestone, PhD1,2; Alexandra J. Lorentz, PhD1; Xiong Wang, PhD, DVM1; Kathryn Como-Sabetti, MPH1; Sara Vetter, PhD1; Kirk Smith, PhD, DVM1; Stacy Holzbauer, DVM1,3; Stephanie Meyer, MPH1; Kristin Ehresmann, MPH1; Richard Danila, PhD1; Ruth Lynfield, MD1 (View author affiliations)View suggested citation
Views equals page views plus PDF downloads
On January 9, 2021, the Minnesota Department of Health (MDH) announced the identification of the SARS-CoV-2 variant of concern (VOC) B.1.1.7, also referred to as 20I/501Y.V1 and VOC 202012/01, in specimens from five persons; on January 25, MDH announced the identification of this variant in specimens from three additional persons. The B.1.1.7 variant, which is reported to be more transmissible than certain other SARS-CoV-2 lineages*,† (1), was first reported in the United Kingdom in December 2020 (1). As of February 14, 2021, a total of 1,173 COVID-19 cases of the B.1.1.7 variant had been identified in 39 U.S. states and the District of Columbia (2). Modeling data suggest that B.1.1.7 could become the predominant variant in the United States in March 2021 (3).
The B.1.1.7 variant has a mutation in the spike protein that causes S-gene target failure (SGTF) in the Thermo Fisher Scientific TaqPath COVID-19 reverse transcription–polymerase chain reaction (RT-PCR) assay. The overall RT-PCR result is positive but is negative for the S-gene target and positive for the other two assay targets; SGTF has served as a proxy for identifying the B.1.1.7 variant (1). The MDH Public Health Laboratory (MDH-PHL) requested SARS-CoV-2 RT-PCR–positive specimens with SGTFs collected during November 1, 2020–January 12, 2021, from clinical laboratories that used the TaqPath assay, and 30 specimens were received. An additional specimen that had been collected from a household contact of a person with an SGTF specimen was requested and obtained from a clinical laboratory using another COVID-19 assay that does not detect SGTFs. MDH-PHL conducted whole genome sequencing to analyze the 31 specimens.§
The SARS-CoV-2 variant B.1.1.7 was identified in eight specimens from Minnesota residents, including six (19%) of the 31 specimens sequenced by MDH-PHL and two specimens sequenced through CDC’s national SARS-CoV-2 surveillance system.¶ The eight specimens were collected during December 18, 2020–January 11, 2021, from eight Minnesota residents in five counties in the Minneapolis–St. Paul metropolitan area. Seven persons were interviewed after receiving positive SARS-CoV-2 test results; after those with the B.1.1.7 variant were identified, MDH case investigators recontacted the patients to obtain additional information on exposures and close contacts. Six of the eight patients were successfully contacted, including one who had not been interviewed previously. This activity was reviewed by CDC and was conducted consistent with applicable federal law and policy.**
The eight persons from whom the specimens were collected ranged in age from 15 to 41 years. Three persons had a history of international travel during the 14 days before illness onset, including two who traveled to West Africa (MN-MDH-2252 and MN-MDH-2254) (Figure) and one who traveled to the Dominican Republic (MN-CDC-STM-0000013). Three additional persons traveled to California (MN-MDH-2415, MN-MDH-2416, and MN-CDC-STM-153) in the 14 days before illness onset or specimen collection, including one who received a positive test result while in California and isolated there before returning to Minnesota. Five persons reported COVID-19–like symptoms and had illness onset dates during December 16, 2020–January 10, 2021; three were asymptomatic. Two sequences (MN-MDH-2253 and MN-MDH-2255) were identical, and the MN-MDH-2252 sequence differed by one single nucleotide variant (SNV). The three sequences for cases from California clustered together within one to three SNVs and are genetically distinct from the other sequences. Two specimens from international travelers, MN-MDH-2254 and MN-CDC-STM-0000013, did not have sequences similar to those identified in Minnesota.
Persons identified with the variant B.1.1.7 in Minnesota had exposure histories related to travel (six), the household (one), and others in the community (one). None had a history of travel to the United Kingdom, although three persons traveled internationally and three persons traveled domestically in the 14 days before illness onset or specimen collection, including one who received a positive test result before returning to Minnesota. Identification of this variant in Minnesota, a variant that epidemiologic and genomic evidence suggests has increased transmissibility, highlights the importance of mitigation measures such as mask use, physical distancing, avoiding crowds and poorly ventilated indoor spaces, isolation of persons with diagnosed COVID-19, quarantine of close contacts of persons with COVID-19,†† and adherence to CDC travel guidance§§ to slow transmission. As SARS-CoV-2 continues to evolve, timely genomic surveillance and disease mitigation strategies will be critical for monitoring variant emergence and protecting public health.
Patients described in this report; University of Minnesota Genomics Center; M Health Fairview Molecular Diagnostics Laboratory, Minneapolis, Minnesota; M Health Fairview Infectious Disease Diagnostic Laboratory, Minneapolis, Minnesota, and clinical laboratories; Brittney Bailey; Brooke Wiedinmyer; Jessica van Oploo; Jennifer Plum; Lensa Terfa; Sarah A. Henry; Matthew Plumb; Jacob Garfin.
Corresponding author: Melanie Firestone, firstname.lastname@example.org
1Minnesota Department of Health; 2Epidemic Intelligence Service, CDC; 3Division of State and Local Readiness, Center for Preparedness and Response, CDC.
All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.
** 45 C.F.R. part 46, 21 C.F.R. part 56; 42 U.S.C. Sect. 241(d); 5 U.S.C. Sect. 552a; 44 U.S.C. Sect. 3501 et seq.
- Public Health England. Investigation of novel SARS-COV-2 variant: variant of concern 202012/01. London, United Kingdom: Public Health England; 2020. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/947048/Technical_Briefing_VOC_SH_NJL2_SH2.pdf
- CDC. U.S. COVID-19 cases caused by variants. Atlanta, GA: US Department of Health and Human Services, CDC; 2021. https://www.cdc.gov/coronavirus/2019-ncov/transmission/variant-cases.html
- Galloway SE, Paul P, MacCannell DR, et al. Emergence of SARS-CoV-2 B.1.1.7 lineage—United States, December 29, 2020–January 12, 2021. MMWR Morb Mortal Wkly Rep 2021;70:95–9. https://doi.org/10.15585/mmwr.mm7003e2 PMID:33476315
FIGURE. Phylogenetic tree* showing genetic distance† between SARS-CoV-2–positive specimens with the B.1.1.7 variant (n = 8) and exposure histories related to travel,§ household contacts, and others in the community
Abbreviation: SNV = single nucleotide variant.
* Phylogenetic tree created using Interactive Tree of Life (version 5.7; European Molecular Biology Laboratory). https://itol.embl.de/
† MN-MDH-2253 and MN-MDH-2255 were identical, and MN-MDH-2252 was within one SNV. MN-MDH-2252 and MN-MDH-2253 were collected from persons who were household contacts. Two specimens from international travelers, MN-MDH-2254 and MN-CDC-STM-0000013, did not have sequences similar to those identified in Minnesota.
§ International and domestic travel occurred during the 14 days before illness onset or specimen collection, including onset of illness in persons who received positive SARS-CoV-2 test results while away from Minnesota. MN-CDC-STM-153, MN-MDH-2416, and MN-MDH-2415 were clustered together within one to three SNVs. These three specimens were from persons who reported travel to California in the 14 days before illness onset or specimen collection, including one who received a positive test result while in California and isolated there before returning to Minnesota.
Suggested citation for this article: Firestone MJ, Lorentz AJ, Wang X, et al. First Identified Cases of SARS-CoV-2 Variant B.1.1.7 in Minnesota — December 2020–January 2021. MMWR Morb Mortal Wkly Rep 2021;70:278–279. DOI: http://dx.doi.org/10.15585/mmwr.mm7008e1.
MMWR and Morbidity and Mortality Weekly Report are service marks of the U.S. Department of Health and Human Services.
Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.
References to non-CDC sites on the Internet are provided as a service to MMWR readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of pages found at these sites. URL addresses listed in MMWR were current as of the date of publication.
All HTML versions of MMWR articles are generated from final proofs through an automated process. This conversion might result in character translation or format errors in the HTML version. Users are referred to the electronic PDF version (https://www.cdc.gov/mmwr) and/or the original MMWR paper copy for printable versions of official text, figures, and tables.
Questions or messages regarding errors in formatting should be addressed to email@example.com.